The estimated Net Worth of Russell Kevin Klass is at least $254 Mille dollars as of 12 June 2024. Russell Klass owns over 299,993 units of Zomedica Pharmaceuticals stock worth over $254,206 and over the last few years Russell sold ZOM stock worth over $0.
Russell has made over 2 trades of the Zomedica Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently Russell bought 299,993 units of ZOM stock worth $47,999 on 12 June 2024.
The largest trade Russell's ever made was buying 700,007 units of Zomedica Pharmaceuticals stock on 10 June 2024 worth over $105,001. On average, Russell trades about 250,000 units every 1 days since 2023. As of 12 June 2024 Russell still owns at least 2,000,050 units of Zomedica Pharmaceuticals stock.
You can see the complete history of Russell Klass stock trades at the bottom of the page.
Russell's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48108.
Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers e Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include: